Affymetrix & Ariosa Diagnostics Announce Signing of Multi-Year Supply Agreement in Support of Ariosa’s Non-Invasive Prenata...
October 16 2014 - 6:30AM
Business Wire
Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today
announced the signing of a multi-year supply agreement covering
Affymetrix arrays and instruments to be utilized as part of
Ariosa’s Harmony™ Non-Invasive Prenatal Test (NIPT). The
partnership enables Ariosa to pursue the development of a Harmony
test kit that will allow other laboratories around the world to
adopt and perform this test. This announcement follows the recent
publication of a study in Fetal Diagnosis and Therapy online in
which Ariosa’s scientists successfully tested and implemented
Affymetrix microarrays as part of a DNA quantification method for
the Harmony test. The study demonstrated better performance of
Affymetrix microarrays in comparison to a next generation
sequencing approach in regard to shorter turn-around time and
improved precision in measuring chromosome concentration and fetal
fraction of cell-free DNA.
“We are pleased with the Affymetrix partnership as they have
been a solid and reliable supplier. Our work on the microarray
opens up the possibility to further broaden access to the Harmony
test via a kit decentralization strategy,” said Ken Song, CEO of
Ariosa. “We are excited about the opportunity to improve prenatal
care for women globally.”
Ariosa Diagnostics is a partner in the Affymetrix’s Powered by
Affymetrix™ Program. “Our array and assay technologies are
foundational genomic tools in reproductive health and oncology
applications. Our partners are providing innovative solutions for
unmet needs in these critical areas,” said Frank Witney, President
and CEO of Affymetrix. “We are pleased to work with Ariosa to
supply arrays and instrumentation in support of their global
business strategy.”
About the Harmony Test
The Harmony prenatal test is a non-invasive blood test for
pregnant women that can be used as early as 10 weeks into
pregnancy. By evaluating cell-free DNA found in maternal blood, the
test can assess the risk of Trisomy 21 (Down syndrome) in the
fetus. It has been validated with the largest clinical data set in
the prenatal cell-free DNA space, making it the most broadly
studied cell-free DNA test. It is available in more than 90
countries and has been used to guide clinical care in over 350,000
pregnancies worldwide.
About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a leading global molecular
diagnostics company committed to improving overall patient care by
developing and delivering innovative, affordable, and
widely-accessible testing. Tests are fully validated by
rigorous and comprehensive methodologies, to ensure health care
practitioners and patients can be confident in the test’s
performance. Ariosa has developed leading-edge technologies to
perform a directed analysis of cell-free DNA in blood. The company
is headquartered in San Jose, California. For more information,
visit www.ariosadx.com.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141016005241/en/
Affymetrix Contacts:Media Contact:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorAriosa Diagnostics Media
Contact:Margaret Theeuwes, 408-229-5180Vice President,
Marketingmtheeuwes@ariosadx.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024